Genelux (United States)

Genelux (United States)

Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Derived from Wikipedia licensed CC-BY-SA.

Open Access statistics for Genelux (United States), United States, covering academic research published from 2003 to 2023. Read More.


Open Access Percentage

67%


Total
Publications

136


Total Open
Publications

91


Total
Citations

4.7K


Open Access
Percentage

67%


Total
Publications

136


Total Open
Publications

91


Total
Citations

4.7K

Wikipedia

Website

download

Breakdown

19% 38% 10% 33%

Publisher Open

19%

Both

38%

Other Platform Open

10%

Closed

33%

Percentage of Open Access over time

200320042005200620072008200920102011201220132014201520162017201820192020202120222023

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

0246810121416182022Total Publications
200320042005200620072008200920102011201220132014201520162017201820192020202120222023

Open

Closed

Publisher Open

62%OA Journal

OA Journal 62%

48

Hybrid 9%

7

No Guarantees 29%

22

Other Platform Open

Domain 73%

48

Institution 32%

21

Other Internet 32%

21

Public 12%

8

Preprint 0%

0

Other Platform Locations

Name

Platform Type

Publications

PubMed Central
Domain
48
DOI
Other Internet
22
Würzburg University - Online Publication Service of Würzburg University
Institution
16
Figshare
Public
8
Europe PMC
Domain
7
Unknown Repository
Other Internet
1
University of Milano-Bicocca - BOA
Institution
1
University of Granada - Institutional Repository of the University of Granada
Institution
1
University of Genoa - CINECA IRIS Institutial Research Information System
Institution
1
Universita Degli Studi Di Milano - Archivio Istituzionale della Ricerca
Institution
1
1 / 2

Data updated 18 August 2025

Share

Share

Share